Search / Trial NCT00001874

Technical Evaluation of Cardiovascular Magnetic Resonance Imaging and Spectroscopy

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Nov 3, 1999

Trial Information

Current as of December 26, 2024

Completed

Keywords

Imaging Spectroscopy Mri Cardiovascular Technical Development Safety Gadolinium Heart Toxicity Adverse Events Normal Volunteer

ClinConnect Summary

Technical evaluation of magnetic resonance imaging and spectroscopy will be performed on normal volunteers. These studies will be conducted in the NIH MRI systems located in Suburban Hospital in Bethesda, Maryland. These studies may involve the intravenous administration of commercially available MR contrast media and exercise. The results will be used to evaluate the performance of various pulse sequences, gradient coils, and RF coils on human subjects and will provide essential ground work for specific patient protocols.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Any normal volunteer above the age 18 who is capable of giving informed consent will be included.
  • EXCLUSION CRITERIA:
  • A subject will be excluded if he/she has a contradiction to MR scanning.
  • 1. Brain aneurysm clip
  • 2. Implanted neural stimulator
  • 3. Implanted cardiac pacemaker implanted defibrillator
  • 4. Cochlear implant
  • 5. Ocular foreign body (e.g. metal shavings)
  • 6. Insulin pump
  • 7. Pregnant women (when uncertain, subjects will undergo urine or blood testing).
  • 8. Kidney
  • 9. Paralyzed hemidiaphragm
  • 10. Morbid obesity
  • 11. Claustrophobia
  • 12. Any condition in the PI's judgement which present unncessary risk
  • EXCLUSION CRITERIA FOR GADOLINIUM ENHANCED STUDIES:
  • 1. Lactating women
  • 2. Subjects with hemoglobinopathies
  • 3. Asthma
  • 4. Renal or hepatic disease
  • Subjects will be excluded if it is deemed that they have a condition that would preclude their use for technical development (e.g. paralyzed hemidiaphragm, morbid obesity, claustrophobia etc.) or present unnecessary risk (e.g. pregnancy, surgery of uncertain type, etc.).
  • Lactating women and subjects with hemoglobinopathies, asthma, or renal or hepatic disease will be excluded from studies involving the adminstration of contrast agents.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials